Authors
Annette M Molinaro, Shawn Hervey-Jumper, Ramin A Morshed, Jacob Young, Seunggu J Han, Pranathi Chunduru, Yalan Zhang, Joanna J Phillips, Anny Shai, Marisa Lafontaine, Jason Crane, Ankush Chandra, Patrick Flanigan, Arman Jahangiri, Gino Cioffi, Quinn Ostrom, John E Anderson, Chaitra Badve, Jill Barnholtz-Sloan, Andrew E Sloan, Bradley J Erickson, Paul A Decker, Matthew L Kosel, Daniel LaChance, Jeanette Eckel-Passow, Robert Jenkins, Javier Villanueva-Meyer, Terri Rice, Margaret Wrensch, John K Wiencke, Nancy Ann Oberheim Bush, Jennie Taylor, Nicholas Butowski, Michael Prados, Jennifer Clarke, Susan Chang, Edward Chang, Manish Aghi, Philip Theodosopoulos, Michael McDermott, Mitchel S Berger
Publication date
2020/4/1
Journal
JAMA oncology
Volume
6
Issue
4
Pages
495-503
Publisher
American Medical Association
Description
Importance
Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)–wild-type andIDH-mutant subtypes, with median patient survival of 1.2 and 3.6 years, respectively. Although maximal resection of contrast-enhanced (CE) tumor is associated with longer survival, the prognostic importance of maximal resection within molecular subgroups and the potential importance of resection of non–contrast-enhanced (NCE) disease is poorly understood.
Objective
To assess the association of resection of CE and NCE tumors in conjunction with molecular and clinical information to develop a new road map for cytoreductive surgery.
Design, Setting, and Participants
This retrospective, multicenter cohort study included a development cohort from the University of California, San Francisco (761 patients diagnosed from January 1 …
Scholar articles
AM Molinaro, S Hervey-Jumper, RA Morshed, J Young… - JAMA oncology, 2020